{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Inhaled prostanoids",
      "Prostacyclins",
      "Prostanoids",
      "Pulmonary arterial hypertension",
      "Transition"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "31912412",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "31"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "07",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "01",
        "Day": "07"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/s00408-019-00306-4"
    ],
    "Journal": {
      "ISSN": "1432-1750",
      "JournalIssue": {
        "Volume": "198",
        "Issue": "1",
        "PubDate": {
          "Year": "2020",
          "Month": "Feb"
        }
      },
      "Title": "Lung",
      "ISOAbbreviation": "Lung"
    },
    "ArticleTitle": "Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.",
    "Pagination": {
      "StartPage": "53",
      "EndPage": "58",
      "MedlinePgn": "53-58"
    },
    "Abstract": {
      "AbstractText": [
        "The intravenous or subcutaneous delivery of prostanoid drugs for moderate to severe pulmonary arterial hypertension has been fraught with complications and patient dissatisfaction. Combination therapy including inhaled treprostinil is an attractive alternative in clinically stable patients. Uncertainties exist about the patient characteristics and the optimal setting (inpatient versus office/home) for transition.",
        "Sixteen stable patients with pulmonary arterial hypertension and favorable risk profile were transitioned from parenteral prostanoid to combination therapy including inhaled treprostinil in the home setting. Nine patients were using intravenous treprostinil, two patients were using subcutaneous treprostinil, and five patients were using intravenous epoprostenol at a median dose of 80 (interquartile range, IQR 72-90), 76.5 (68 and 85), and 28 (IQR 26-30) ng/kg/min respectively. Patients were followed up for a median of 732.5\u00a0days after transition (IQR 506.5-1294\u00a0days).",
        "Patients tolerated the transition to inhaled treprostinil well without significant change in functional class (81.25% FC I/II before transition vs. 87.5% after), 6-min walk distance [349\u00a0m (IQR 226-461\u00a0m) to 364\u00a0m (IQR 238-565\u00a0m), p\u2009=\u20090.09] or NT-proBNP [149\u00a0pg/ml (IQR 71.5-383\u00a0pg/ml) to 186.5\u00a0pg/ml (IQR 83.5-444\u00a0pg/ml), p\u2009=\u20090.38]. Hemodynamic data, where available, showed significant improvements in mean pulmonary artery pressure and pulmonary vascular resistance from 36\u00a0mmHg (IQR 27-46.5\u00a0mmHg) and 5.2 Wood Units (WU) (IQR 3.1-5.6 WU) to 28.5\u00a0mmHg (IQR 22-35.5\u00a0mmHg) and 3.2 WU (IQR 2.4-4.2 WU) (p-values 0.022 and 0.003). More patients were on triple therapy after transition, and side effects reported were less severe.",
        "For select patients, transition from a parenteral prostanoid-based therapy to a combination regimen including inhaled treprostinil in the home setting appears safe and well tolerated."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-8297-0278"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Section of Pulmonary and Critical Care Medicine, The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA."
          }
        ],
        "LastName": "Kimmig",
        "ForeName": "Lucas M",
        "Initials": "LM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Public Health Sciences, The University of Chicago, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA."
          }
        ],
        "LastName": "Liao",
        "ForeName": "Chuanhong",
        "Initials": "C"
      },
      {
        "Identifier": [
          "0000-0001-8313-6015"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Section of Pulmonary and Critical Care Medicine, The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA. rbag@bsd.uchicago.edu."
          },
          {
            "Identifier": [],
            "Affiliation": "Biological Sciences Division, The University of Chicago, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA. rbag@bsd.uchicago.edu."
          }
        ],
        "LastName": "Bag",
        "ForeName": "Remzi",
        "Initials": "R"
      }
    ],
    "GrantList": [
      {
        "GrantID": "T32 HL007605",
        "Acronym": "HL",
        "Agency": "NHLBI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Lung",
    "NlmUniqueID": "7701875",
    "ISSNLinking": "0341-2040"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antihypertensive Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Peptide Fragments"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "pro-brain natriuretic peptide (1-76)"
    },
    {
      "RegistryNumber": "114471-18-0",
      "NameOfSubstance": "Natriuretic Peptide, Brain"
    },
    {
      "RegistryNumber": "DCR9Z582X0",
      "NameOfSubstance": "Epoprostenol"
    },
    {
      "RegistryNumber": "RUM6K67ESG",
      "NameOfSubstance": "treprostinil"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Inhalation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Ambulatory Care"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Antihypertensive Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cardiac Catheterization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Substitution"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Echocardiography"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "analogs & derivatives",
        "therapeutic use"
      ],
      "DescriptorName": "Epoprostenol"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Exercise Test"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Infusions, Intravenous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Infusions, Subcutaneous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Natriuretic Peptide, Brain"
    },
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Peptide Fragments"
    },
    {
      "QualifierName": [
        "blood",
        "diagnostic imaging",
        "drug therapy",
        "physiopathology"
      ],
      "DescriptorName": "Pulmonary Arterial Hypertension"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Walk Test"
    }
  ]
}